Skip to main content
SpringerLink
Log in

Drug Resistance in Hepatocellular Carcinoma

  • Chapter
  • First Online:
Hepatobiliary Cancers: An Interdisciplinary Approach

Part of the book series: Interdisciplinary Cancer Research ((ICR,volume 3))

Abstract

At present, the burden of cancer morbidity and mortality is increasing all over the world. Among all kinds of cancer, primary liver cancer is discovered to be the seventh most common cancer and has an extremely high death rate, affecting countless patients. Globally, the main histology of primary liver cancer is hepatocellular carcinoma (HCC), characterized by pathological changes in parenchymal cells of the liver, accounting for over 70% of liver cancer. Currently, HCC treatment mainly includes surgical intervention, local ablative therapy, and local therapy. Sorafenib, a multityrosine kinase inhibitor, is approved for use in patients with unresectable HCC. Tyrosine kinase inhibitors (TKIs) (lenvatinib, regorafenib, and cabozantinib) and a VEGF receptor inhibitor (ramucirumab) have also been used for HCC treatment. Although drugs for HCC treatment have been under further development, the acquired drug resistance increasingly affects the management of HCC patients. Researchers have focused on drug resistance for many years and identified complex regulatory networks involved in this issue. In this chapter, the significant research progress regarding mechanisms underlying HCC drug resistance is summarized, which may benefit the treatment of HCC patients and give future direction for new drug development for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Al-Salama ZT, Syed YY, Scott LJ (2019) Lenvatinib: a review in hepatocellular carcinoma. Drugs 79:665–674

    CAS  PubMed  Google Scholar 

  • Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F (2021) ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 74:893–906

    CAS  PubMed  Google Scholar 

  • Augello G, Emma MR, Azzolina A, Puleio R, Condorelli L, Cusimano A, Giannitrapani L, McCubrey JA, Iovanna JL, Cervello M (2021) The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. Cancer Lett 519:250–262

    CAS  PubMed  Google Scholar 

  • Barot S, Abo-Ali EM, Zhou DL, Palaguachi C, Dukhande VV (2019) Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells. Exp Cell Res 381:288–300

    CAS  PubMed  Google Scholar 

  • Cao Y, Zhang F, Wang H, Bi C, Cui J, Liu F, Pan H (2021) LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis. Mol Cell Biochem 476:279–292

    CAS  PubMed  Google Scholar 

  • Chen Q-N, Wei C-C, Wang Z-X, Sun M (2017) Long non-coding RNAs in anti-cancer drug resistance. Oncotarget 8:1925–1936

    PubMed  Google Scholar 

  • Chen S, Cao Q, Wen W, Wang H (2019a) Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett 460:1–9

    CAS  PubMed  Google Scholar 

  • Chen H, Liu S, Li M, Huang P, Li X (2019b) circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt/β-catenin pathway in hepatocellular carcinoma. Onco Targets Ther 12:9539–9549

    CAS  PubMed  PubMed Central  Google Scholar 

  • Chen Y, Zhao H, Li H, Feng X, Tang H, Qiu C, Zhang J, Fu B (2020) LINC01234/MicroRNA-31-5p/MAGEA3 axis mediates the proliferation and chemoresistance of hepatocellular carcinoma cells. Mol Ther Nucleic Acids 19:168–178

    CAS  PubMed  Google Scholar 

  • Cheng L, Luo S, Jin C, Ma H, Zhou H, Jia L (2013) FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death Dis 4:e923–e923

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ding K, Liao Y, Gong D, Zhao X, Ji W (2018a) Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun 502:194–201

    CAS  PubMed  Google Scholar 

  • Ding B, Lou W, Xu L, Fan W (2018b) Non-coding RNA in drug resistance of hepatocellular carcinoma. Biosci Rep 38:BSR20180915

    PubMed  PubMed Central  Google Scholar 

  • Ding B, Bao C, Jin L, Xu L, Fan W, Lou W (2021) CASK silence overcomes sorafenib resistance of hepatocellular carcinoma through activating apoptosis and autophagic cell death. Front Oncol 11:681683–681683

    CAS  PubMed  PubMed Central  Google Scholar 

  • Du Z, Niu S, Xu X, Xu Q (2017) MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance. Cancer Biomark 19:221–230

    CAS  PubMed  Google Scholar 

  • Ergun S, Oztuzcu S (2015) Oncocers: ceRNA-mediated cross-talk by sponging miRNAs in oncogenic pathways. Tumour Biol 36:3129–3136

    CAS  PubMed  Google Scholar 

  • Facciorusso A, Abd El Aziz MA, Sacco R (2019) Efficacy of regorafenib in hepatocellular carcinoma patients: a systematic review and meta-analysis. Cancer 12:36

    Google Scholar 

  • Fan L, Huang X, Chen J, Zhang K, Gu YH, Sun J, Cui SY (2020) Long noncoding RNA MALAT1 contributes to sorafenib resistance by targeting miR-140-5p/Aurora-A signaling in hepatocellular carcinoma. Mol Cancer Ther 19:1197–1209

    CAS  PubMed  Google Scholar 

  • Fan W, Chen L, Wu X, Zhang T (2021) Circ_0031242 silencing mitigates the progression and drug resistance in DDP-resistant hepatoma cells by the miR-924/POU3F2 axis. Cancer Manag Res 13:743–755

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fu X-D (2014) Non-coding RNA: a new frontier in regulatory biology. Natl Sci Rev 1:190–204

    CAS  PubMed  Google Scholar 

  • Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T, Wen H, Yang Y, Wang S, Wang J, Nan K, Yao Y, Tian T (2018) Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res 37:52–52

    PubMed  PubMed Central  Google Scholar 

  • Fu X-T, Song K, Zhou J, Shi Y-H, Liu W-R, Shi G-M, Gao Q, Wang X-Y, Ding Z-B, Fan J (2019) Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. Cancer Cell Int 19:71–71

    PubMed  PubMed Central  Google Scholar 

  • Galle E, Thienpont B, Cappuyns S, Venken T, Busschaert P, Van Haele M, Van Cutsem E, Roskams T, van Pelt J, Verslype C, Dekervel J, Lambrechts D (2020) DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin Epigenetics 12:27–27

    CAS  PubMed  PubMed Central  Google Scholar 

  • Golkowski M, Lau HT, Chan M, Kenerson H, Vidadala VN, Shoemaker A, Maly DJ, Yeung RS, Gujral TS, Ong SE (2020) Pharmacoproteomics identifies kinase pathways that drive the epithelial-mesenchymal transition and drug resistance in hepatocellular carcinoma. Cell Syst 11:196–207.e197

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F (2020) MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma. Cancer Res 80:1720–1734

    CAS  PubMed  Google Scholar 

  • Guo Z, Zhang J, Fan L, Liu J, Yu H, Li X, Sun G (2019) Long noncoding RNA (lncRNA) small nucleolar RNA host Gene 16 (SNHG16) predicts poor prognosis and sorafenib resistance in hepatocellular carcinoma. Med Sci Monit 25:2079–2086

    CAS  PubMed  PubMed Central  Google Scholar 

  • Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X (2017) Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Mol Oncol 11:320–334

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hu H, Yang L, Li L, Zeng C (2018) Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ ABCC1 axis. Biochem Biophys Res Commun 503:2400–2406

    CAS  PubMed  Google Scholar 

  • Hu B, Cheng J-W, Hu J-W, Li H, Ma X-L, Tang W-G, Sun Y-F, Guo W, Huang A, Zhou K-Q, Gao P-T, Cao Y, Qiu S-J, Zhou J, Fan J, Yang X-R (2019) KPNA3 confers sorafenib resistance to advanced hepatocellular carcinoma via TWIST regulated epithelial-mesenchymal transition. J Cancer 10:3914–3925

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang H, Chen J, Ding C-M, Jin X, Jia Z-M, Peng J (2018) LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. J Cell Mol Med 22:3238–3245

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huang X-Y, Zhang P-F, Wei C-Y, Peng R, Lu J-C, Gao C, Cai J-B, Yang X, Fan J, Ke A-W, Zhou J, Shi G-M (2020) Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer 19:92–92

    CAS  PubMed  PubMed Central  Google Scholar 

  • Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, Cai L, Xu J, Cai X (2020) miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis 11:250–250

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang C-Y, Zen K, Li L (2017) MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 8:e2540–e2540

    PubMed  PubMed Central  Google Scholar 

  • Kabir TD, Ganda C, Brown RM, Beveridge DJ, Richardson KL, Chaturvedi V, Candy P, Epis M, Wintle L, Kalinowski F, Kopp C, Stuart LM, Yeoh GC, George J, Leedman PJ (2018) A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology 67:216–231

    CAS  PubMed  Google Scholar 

  • Kelley RK, Mollon P, Blanc J-F, Daniele B, Yau T, Cheng A-L, Valcheva V, Marteau F, Guerra I, Abou-Alfa GK (2020) Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther 37:2678–2695

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ko K-L, Mak L-Y, Cheung K-S, Yuen M-F (2020) Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Research 9:1620

    Google Scholar 

  • Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J (2019) The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet 20:675–691

    CAS  PubMed  Google Scholar 

  • Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, Baron A, Park J-W, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng A-L (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173

    CAS  PubMed  Google Scholar 

  • Lai H-H, Li C-W, Hong C-C, Sun H-Y, Chiu C-F, Ou D-L, Chen P-S (2019) TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Mol Oncol 13:928–945

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li Y, Ye Y, Feng B, Qi Y (2017) Long noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway. J Cell Biochem 118:4498–4507

    CAS  PubMed  Google Scholar 

  • Li J, Wu P-W, Zhou Y, Dai B, Zhang P-F, Zhang Y-H, Liu Y, Shi X-L (2018) Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy. Cell Death Dis 9:225–225

    PubMed  PubMed Central  Google Scholar 

  • Li W, Dong X, He C, Tan G, Li Z, Zhai B, Feng J, Jiang X, Liu C, Jiang H, Sun X (2019) LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res 38:183–183

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li X, Ding J, Wang X, Cheng Z, Zhu Q (2020a) NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma. Oncogene 39:891–904

    PubMed  Google Scholar 

  • Li X, He J, Ren X, Zhao H, Zhao H (2020b) Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway. Diagn Pathol 15:141

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li J, Qin X, Wu R, Wan L, Zhang L, Liu R (2020c) Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis. J Cell Mol Med 24:5152–5161

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li X, Zhou Y, Yang L, Ma Y, Peng X, Yang S, Li H, Liu J (2020d) LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma. J Cell Physiol 235:3402–3413

    CAS  PubMed  Google Scholar 

  • Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G (2020) RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J 39:e103181–e103181

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ling S, Li J, Shan Q, Dai H, Lu D, Wen X, Song P, Xie H, Zhou L, Liu J, Xu X, Zheng S (2017) USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. Mol Oncol 11:682–695

    CAS  PubMed  PubMed Central  Google Scholar 

  • Liu K, Liu S, Zhang W, Ji B, Wang Y, Liu Y (2014) miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int J Oncol 45:1537–1546

    CAS  PubMed  Google Scholar 

  • Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15:599–616

    PubMed  Google Scholar 

  • Long J, Bai Y, Yang X, Lin J, Yang X, Wang D, He L, Zheng Y, Zhao H (2019) Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell Int 19:90–90

    PubMed  PubMed Central  Google Scholar 

  • Lu TX, Rothenberg ME (2018) MicroRNA. J Allergy Clin Immunol 141:1202–1207

    CAS  PubMed  Google Scholar 

  • Lu S, Yao Y, Xu G, Zhou C, Zhang Y, Sun J, Jiang R, Shao Q, Chen Y (2018) CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis 9:646–646

    PubMed  PubMed Central  Google Scholar 

  • Luo D, Wang Z, Wu J, Jiang C, Wu J (2014) The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int 2014:409272

    PubMed  PubMed Central  Google Scholar 

  • Ma Z, Guo D, Wang Q, Liu P, Xiao Y, Wu P, Wang Y, Chen B, Liu Z, Liu Q (2019) Lgr5-mediated p53 repression through PDCD5 leads to doxorubicin resistance in hepatocellular carcinoma. Theranostics 9:2967–2983

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ma Y, Wen J, Wang J, Wang C, Zhang Y, Zhao L, Li J, Feng X (2020) Asiaticoside antagonizes proliferation and chemotherapeutic drug resistance in hepatocellular carcinoma (HCC) cells. Med Sci Monit 26:e924435–e924435

    CAS  PubMed  PubMed Central  Google Scholar 

  • Matsui M, Corey DR (2017) Non-coding RNAs as drug targets. Nat Rev Drug Discov 16:167–179

    CAS  PubMed  Google Scholar 

  • Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J (2018) Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 7:2641–2653

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mattick JS, Makunin IV (2006) Non-coding RNA. Hum Mol Genet 15:R17–R29

    CAS  PubMed  Google Scholar 

  • McGlynn KA, Petrick JL, London WT (2015) Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 19:223–238

    PubMed  PubMed Central  Google Scholar 

  • Mou S-J, Yang P-F, Liu Y-P, Xu N, Jiang W-W, Yue W-J (2020) BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci 242:117177

    CAS  PubMed  Google Scholar 

  • Najafi M, Mortezaee K, Majidpoor J (2019) Cancer stem cell (CSC) resistance drivers. Life Sci 234:116781

    CAS  PubMed  Google Scholar 

  • Nie J, Lin B, Zhou M, Wu L, Zheng T (2018) Role of ferroptosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 144:2329–2337

    CAS  PubMed  Google Scholar 

  • Nwosu ZC, PioroÅ„ska W, Battello N, Zimmer AD, Dewidar B, Han M, Pereira S, Blagojevic B, Castven D, Charlestin V, Holenya P, Lochead J, De La Torre C, Gretz N, Sajjakulnukit P, Zhang L, Ward MH, Marquardt JU, di Magliano MP, Lyssiotis CA, Sleeman J, Wölfl S, Ebert MP, Meyer C, Hofmann U, Dooley S (2020) Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. EBioMedicine 54:102699–102699

    PubMed  PubMed Central  Google Scholar 

  • Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT (2019) Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 25:2279–2293

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ohata Y, Shimada S, Akiyama Y, Mogushi K, Nakao K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M, Tanaka S (2017) Acquired resistance with epigenetic alterations under long-term antiangiogenic therapy for hepatocellular carcinoma. Mol Cancer Ther 16:1155–1165

    CAS  PubMed  Google Scholar 

  • Pan JJ, Xie XJ, Li X, Chen W (2015) Long non-coding RNAs and drug resistance. Asian Pac J Cancer Prev 16:8067–8073

    PubMed  Google Scholar 

  • Personeni N, Pressiani T, Santoro A, Rimassa L (2018) Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs Context 7:212533–212533

    PubMed  PubMed Central  Google Scholar 

  • Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, Valery PC, Bray F, McGlynn KA (2020) International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer 147:317–330

    CAS  PubMed  Google Scholar 

  • Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146:353–358

    CAS  PubMed  PubMed Central  Google Scholar 

  • Saw PE, Xu X, Chen J, Song EW (2021) Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci 64:22–50

    CAS  PubMed  Google Scholar 

  • Shao M, Shi R, Gao Z-X, Gao S-S, Li J-F, Li H, Cui S-Z, Hu W-M, Chen T-Y, Wu G-R, Zhang J, Xu J, Sy M-S, Li C (2021) Crizotinib and doxorubicin cooperatively reduces drug resistance by mitigating MDR1 to increase hepatocellular carcinoma cells death. Front Oncol 11:650052–650052

    CAS  PubMed  PubMed Central  Google Scholar 

  • Song Y, Kim JS, Choi EK, Kim J, Kim KM, Seo HR (2017) TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC. Oncotarget 8:21650–21662

    PubMed  PubMed Central  Google Scholar 

  • Su Y-C, Davuluri GVN, Chen C-H, Shiau D-C, Chen C-C, Chen C-L, Lin Y-S, Chang C-P (2016) Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. PLoS One 11:e0148408–e0148408

    PubMed  PubMed Central  Google Scholar 

  • Sui C, Dong Z, Yang C, Zhang M, Dai B, Geng L, Lu J, Yang J, Xu M (2019) LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. J Cell Mol Med 23:6024–6033

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sun G, Mackey LV, Coy DH, Yu C-Y, Sun L (2015) The histone deacetylase inhibitor vaproic acid induces cell growth arrest in hepatocellular carcinoma cells via suppressing notch signaling. J Cancer 6:996–1004

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D (2016) Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64:488–500

    CAS  PubMed  Google Scholar 

  • Tan W, Luo X, Li W, Zhong J, Cao J, Zhu S, Chen X, Zhou R, Shang C, Chen Y (2019) TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine 40:446–456

    PubMed  Google Scholar 

  • Tian N, Han Z, Li Z, Zhou M, Fan C (2014) Lin28/let-7/Bcl-xL pathway: the underlying mechanism of drug resistance in Hep3B cells. Oncol Rep 32:1050–1056

    CAS  PubMed  Google Scholar 

  • Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo C-M, Man K, Ding J, Lee TK, Ma S (2018) Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol 69:826–839

    CAS  PubMed  Google Scholar 

  • Wang XJ, Feng CW, Li M (2013) ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway. Mol Cell Biochem 380:57–66

    CAS  PubMed  Google Scholar 

  • Wang H, Tang Y, Yang D, Zheng L (2019) MicroRNA-591 functions as a tumor suppressor in hepatocellular carcinoma by lowering drug resistance through inhibition of far-upstream element-binding protein 2-mediated phosphoinositide 3-Kinase/Akt/Mammalian target of rapamycin axis. Pharmacology 104:173–186

    CAS  PubMed  Google Scholar 

  • Wang C, Ke S, Li M, Lin C, Liu X, Pan Q (2020a) Downregulation of LncRNA GAS5 promotes liver cancer proliferation and drug resistance by decreasing PTEN expression. Mol Gen Genomics 295:251–260

    CAS  Google Scholar 

  • Wang S, Wang Y, Xun X, Zhang C, Xiang X, Cheng Q, Hu S, Li Z, Zhu J (2020b) Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. J Exp Clin Cancer Res 39:22–22

    PubMed  PubMed Central  Google Scholar 

  • Wei L, Lee D, Law C-T, Zhang MS, Shen J, Chin DW-C, Zhang A, Tsang FH-C, Wong CL-S, Ng IO-L, Wong CC-L, Wong C-M (2019a) Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun 10:4681–4681

    PubMed  PubMed Central  Google Scholar 

  • Wei L, Wang X, Lv L, Liu J, Xing H, Song Y, Xie M, Lei T, Zhang N, Yang M (2019b) The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer 18:147–147

    PubMed  PubMed Central  Google Scholar 

  • Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J (2021) MiR-125b loss activated HIF1α/pAKT loop, leading to transarterial chemoembolization resistance in hepatocellular carcinoma. Hepatology 73:1381–1398

    CAS  PubMed  Google Scholar 

  • Wu F-Q, Fang T, Yu L-X, Lv G-S, Lv H-W, Liang D, Li T, Wang C-Z, Tan Y-X, Ding J, Chen Y, Tang L, Guo L-N, Tang S-H, Yang W, Wang H-Y (2016) ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. J Hepatol 65:314–324

    CAS  PubMed  Google Scholar 

  • Wu L, Pan C, Wei X, Shi Y, Zheng J, Lin X, Shi L (2018) lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. Cell Commun Signal 16:47–47

    PubMed  PubMed Central  Google Scholar 

  • Wu L-L, Cai W-P, Lei X, Shi K-Q, Lin X-Y, Shi L (2019) NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. J Cell Commun Signal 13:99–112

    PubMed  Google Scholar 

  • Wu H, Wang T, Liu Y, Li X, Xu S, Wu C, Zou H, Cao M, Jin G, Lang J, Wang B, Liu B, Luo X, Xu C (2020) Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis. J Exp Clin Cancer Res 39:274–274

    CAS  PubMed  PubMed Central  Google Scholar 

  • Xie C, Zhang L-Z, Chen Z-L, Zhong W-J, Fang J-H, Zhu Y, Xiao M-H, Guo Z-W, Zhao N, He X, Zhuang S-M (2020) A hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in NF kappa B signaling and chemoresistance. Hepatology 71:1660–1677

    CAS  PubMed  Google Scholar 

  • Xiong H, Ni Z, He J, Jiang S, Li X, He J, Gong W, Zheng L, Chen S, Li B, Zhang N, Lyu X, Huang G, Chen B, Zhang Y, He F (2017) LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene 36:3528–3540

    CAS  PubMed  Google Scholar 

  • Xu N, Zhang J, Shen C, Luo Y, Xia L, Xue F, Xia Q (2012) Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 423:826–831

    CAS  PubMed  Google Scholar 

  • Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin R-A, Liang X, Cai X (2020a) CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther 5:298–298

    CAS  PubMed  PubMed Central  Google Scholar 

  • Xu WP, Liu JP, Feng JF, Zhu CP, Yang Y, Zhou WP, Ding J, Huang CK, Cui YL, Ding CH, Zhang X, Lu B, Xie WF (2020b) miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy. Gut 69:1309–1321

    CAS  PubMed  Google Scholar 

  • Xu Y, Liu Y, Li Z, Li H, Li X, Yan L, Mao J, Shen J, Chen W, Xue F (2020c) Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675. Oncol Rep 44:165–173

    CAS  PubMed  PubMed Central  Google Scholar 

  • Xu J, Wan Z, Tang M, Lin Z, Jiang S, Ji L, Gorshkov K, Mao Q, Xia S, Cen D, Zheng J, Liang X, Cai X (2020d) N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer 19:163–163

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yang C, Dong Z, Hong H, Dai B, Song F, Geng L, Lu J, Yang J, Sui C, Xu M (2020) circFN1 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-1205 and regulating E2F1 expression. Mol Ther Nucleic Acids 22:421–433

    CAS  PubMed  PubMed Central  Google Scholar 

  • Yin Z, Ma T, Lin Y, Lu X, Zhang C, Chen S, Jian Z (2018) IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem 119:9419–9432

    CAS  PubMed  Google Scholar 

  • Yu H, Qiu Y, Pang X, Li J, Wu S, Yin S, Han L, Zhang Y, Jin C, Gao X, Hu W, Wang T (2017) Lycorine promotes autophagy and apoptosis via TCRP1/Akt/mTOR axis inactivation in human hepatocellular carcinoma. Mol Cancer Ther 16:2711

    CAS  PubMed  Google Scholar 

  • Yu Y, Wang Y, Xiao X, Cheng W, Hu L, Yao W, Qian Z, Wu W (2019) MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1. Biochem Cell Biol 97:563–570

    CAS  PubMed  Google Scholar 

  • Zang J, Lu D, Xu A (2020) The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function. J Neurosci Res 98:87–97

    CAS  PubMed  Google Scholar 

  • Zhang N, Xie H, Lu W, Li F, Li J, Guo Z (2017) Chloroquine sensitizes hepatocellular carcinoma cells to chemotherapy via blocking autophagy and promoting mitochondrial dysfunction. Int J Clin Exp Pathol 10:10056–10065

    PubMed  PubMed Central  Google Scholar 

  • Zhang PF, Wang F, Wu J, Wu Y, Huang W, Liu D, Huang XY, Zhang XM, Ke AW (2019) LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. J Cell Physiol 234:2788–2794

    CAS  PubMed  Google Scholar 

  • Zhang P-F, Gao C, Huang X-Y, Lu J-C, Guo X-J, Shi G-M, Cai J-B, Ke A-W (2020a) Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer 19:110–110

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang W, Liu Y, Fu Y, Han W, Xu H, Wen L, Deng Y, Liu K (2020b) Long non-coding RNA LINC00160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PIK3R3. Cancer Lett 478:22–33

    CAS  PubMed  Google Scholar 

  • Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong J-S (2020c) The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 11:902–902

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang J, Zhao X, Ma X, Yuan Z, Hu M (2020d) KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells. Int J Mol Med 46:1794–1804

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao L, Hu K, Cao J, Wang P, Li J, Zeng K, He X, Tu PF, Tong T, Han L (2019) lncRNA miat functions as a ceRNA to upregulate sirt1 by sponging miR-22-3p in HCC cellular senescence. Aging (Albany NY) 11:7098–7122

    CAS  PubMed  Google Scholar 

  • Zhong W, Dai Q, Huang Q (2020) Effect of lncRNA KCNQ1OT1 on autophagy and drug resistance of hepatocellular carcinoma cells by targeting miR-338-3p. Cell Mol Biol 66:191–196

    PubMed  Google Scholar 

  • Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, Xie S, Zhang S, Wu Y, Liu H, Zhi X, Ma T, Ni H, Chen J, Chai K, Chen W (2019a) miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis 10:843–843

    PubMed  PubMed Central  Google Scholar 

  • Zhou B, Lu Q, Liu J, Fan L, Wang Y, Wei W, Wang H, Sun G (2019b) Melatonin increases the sensitivity of hepatocellular carcinoma to sorafenib through the PERK-ATF4-Beclin1 pathway. Int J Biol Sci 15:1905–1920

    PubMed  PubMed Central  Google Scholar 

  • Zhou Y, Wang Y, Zhou W, Chen T, Wu Q, Chutturghoon VK, Lin B, Geng L, Yang Z, Zhou L, Zheng S (2019c) YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway. Cancer Cell Int 19:179–179

    PubMed  PubMed Central  Google Scholar 

  • Zhou Y, Huang Y, Dai T, Hua Z, Xu J, Lin Y, Han L, Yue X, Ho L, Lu J, Ai X (2021) LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Biomed Pharmacother 133:111030

    CAS  PubMed  Google Scholar 

  • Zhu Y-J, Zheng B, Wang H-Y, Chen L (2017) New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin 38:614–622

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

This review is supported by the National Natural Science Foundation of China (Grant No. 82172386 and 81922081), the Department of Education of Guangdong Province (Grant No. 2021KTSCX104), the Guangdong Basic and Applied Basic Research Foundation (Grant No. 2022A1515012164), and Shenzhen Science and Technology Program (Grant No. JCYJ20210324104201005).

Author Contributions

C.L. supervises and revises the manuscript. X.C. and J.L. write and edit the manuscript and make the tables. Y.H. provides the professional expertise.

Competing Interests

The authors declare no competing interests.

Author information

Author notes

  1. Xinxin Chen and Jin Li contributed equally to this work.

Authors and Affiliations

  1. Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China

    Xinxin Chen, Jin Li, Yuhong Huang & Chao Liang

  2. Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China

    Chao Liang

  3. State Key Laboratory of Proteomics, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China

    Chao Liang

Authors
  1. Xinxin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuhong Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chao Liang .

Editor information

Editors and Affiliations

  1. Department of Clinical Immunology, Karolinska Institutet, Stockholm, Sweden

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, X., Li, J., Huang, Y., Liang, C. (2023). Drug Resistance in Hepatocellular Carcinoma. In: Rezaei, N. (eds) Hepatobiliary Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research, vol 3. Springer, Cham. https://doi.org/10.1007/16833_2022_110

Download citation

Publish with us

Policies and ethics

Search

Navigation